🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseGLP-1 hepatoprotection — my results so far Page 3

GLP-1 hepatoprotection — my results so far

lori_vegas Tue, Jan 9, 2024 at 3:54 PM 14 replies 2,207 viewsPage 3 of 3
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jan 10, 2024 at 3:10 AM#11
ingrid_STO said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

21 19VanRx_Mike, steve_okc, dave_SLC and 18 others
Reply Quote Save Share Report
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Jan 10, 2024 at 5:54 AM#12
KetoKyle said:
ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…

Thank you for spelling out the reasoning rather than just the conclusion.

22 20oliver_london, tane_welly, Dr.PathRoch and 19 others
Reply Quote Save Share Report
tampaLisa73
Member
312
1,456
Oct 2024
Tampa, FL
Jan 10, 2024 at 8:38 AM#13
ingrid_STO said:
Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

23 21sarah_nash92, FitDadDave, RunnerRach and 20 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TirzTom
Senior Member
2,789
9,876
Feb 2024
Florida
Online
Jan 10, 2024 at 11:22 AM#14

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

24 22SandraNC_45, Dr.EndoIndy, tom_AK and 21 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jan 10, 2024 at 2:06 PM#15

Moderator note: a couple of off-topic posts removed.

25 23PurityPaulOR, MaxMetOK, MounjBrad and 22 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register